Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Intranasal Peptide T: Safety, Toxicity, and Pharmacokinetics in Human Immunodeficiency Virus-1 (HIV-1) Infected Patients.

NCT00000391 is registered in ClinicalTrials.gov with National Institute of Mental Health (NIMH) as lead sponsor.

NCT NCT00000391
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00000391 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Intranasal Peptide T: Safety, Toxicity, and Pharmacokinetics in Human Immunodeficiency Virus-1 (HIV-1) Infected Patients.
Lead sponsor
National Institute of Mental Health (NIMH)
Phase
Phase 1
Overall status
Completed
Start date
January 31, 1988
Completion date
Not reported
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections